Answers are grounded in this paper and cite their sources.
Objectives: to analyze the Zolgensma risk-sharing agreement in the SUS and its capacity to reconcile access to gene therapy with budgetary sustainability. Methods: qualitative, bibliographic and documentary research analyzing Ministry of Health acts, the contract, STF Themes 6 and 1,234, and literature on performance-based agreements. Results: the model links installments to motor outcomes and survival, transferring part of the clinical uncertainty to the manufacturer. Limitation: long-term results are not yet consolidated. Conclusions: the agreement is promising, but its effectiveness depends on independent monitoring, reliable data and transparency.
No takes yet. Share an insight, caveat, or question.
Feliciano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: